ProPhase Labs Lands $1.5M Convertible Loan on Punitive Terms as Cash Runs Dry
PRPH sits 53% above its 52-week low of $0.03 on elevated volume (1.8× avg).
Summary
ProPhase Labs closed a $1.5 million convertible loan from J.J. Astor & Co., netting only $1.02 million. The deal includes a $0.075 conversion price, a personal guarantee from the CEO, and a lien on all assets — an expensive lifeline as the company fights a cash crisis and a going-concern warning.
Key Events · Financing and Capital Events · PRPH
-
High-Cost Convertible Loan Closed
The company entered a $2.085M senior secured convertible note with J.J. Astor & Co., securing $1.5M in funding but walking away with only $1.02M in net proceeds after a $60K origination fee and $420K in reserves and other deductions.
-
Conversion Terms Favor Lender
While the conversion price is set at $0.075 per share — a 63% premium to the current $0.046 stock price — full ratchet anti-dilution and a make-whole provision could effectively drive it lower. On default, the conversion price drops to 80% of the lowest VWAP, and the outstanding amount balloons to 110% plus 19% default interest.
-
CEO Personal Guarantee and Blanket Lien
CEO Ted Karkus personally guaranteed the loan, and the lender received a senior security interest in all company assets, along with a payment waterfall on collections from the bankrupt diagnostics subsidiaries.
-
Mandatory Reverse Split and Nasdaq Relisting
Within 30 days, the company must execute a reverse stock split to push the share price above $1.00 and pursue a Nasdaq relisting — a covenant that highlights the urgency of the situation.
Analysis · PRPH · Life Sciences
Facing a going-concern crisis and a nearly empty treasury, ProPhase Labs has entered a $2.085 million senior secured convertible loan with J.J. Astor & Co., but after fees and reserves it will net just $1.02 million. The note carries a 39% original issue discount, demands weekly repayments from day one, and sets a conversion price of $0.075 — a premium to the current $0.046 stock price, yet aggressive anti-dilution and default provisions could slash that price and trigger a flood of new shares. The lender also secures a blanket lien on all assets, a personal guarantee from CEO Ted Karkus, and a waterfall on collections from the company's bankrupt subsidiaries. While the cash infusion buys time, the cost is extreme: potential dilution could exceed 19.9% of outstanding shares if the note converts, and the mandatory reverse split covenant underscores a desperate scramble to regain Nasdaq compliance.
At the time of this filing, PRPH was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $436.7K. The 52-week trading range was $0.03 to $66.59. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.